220 related articles for article (PubMed ID: 25877186)
1. Cancer: The Ras renaissance.
Ledford H
Nature; 2015 Apr; 520(7547):278-80. PubMed ID: 25877186
[No Abstract] [Full Text] [Related]
2. Targeting RAS: The Elusive Prize.
Bates SE
Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
[No Abstract] [Full Text] [Related]
3. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
[TBL] [Abstract][Full Text] [Related]
5. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
6. The molecular perspective: the ras oncogene.
Goodsell DS
Stem Cells; 1999; 17(4):235-6. PubMed ID: 10437988
[No Abstract] [Full Text] [Related]
7. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
8. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
9. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
10. Slaying RAS with a synthetic lethal weapon.
Bommi-Reddy A; Kaelin WG
Cell Res; 2010 Feb; 20(2):119-21. PubMed ID: 20118966
[No Abstract] [Full Text] [Related]
11. The importance of being K-Ras.
Ellis CA; Clark G
Cell Signal; 2000 Jul; 12(7):425-34. PubMed ID: 10989276
[TBL] [Abstract][Full Text] [Related]
12. [Molecular evolution and a speculative carcinogenesis mechanism for ras p21].
Lü B; Chen J; Qin D; Gu J
Yi Chuan Xue Bao; 1990; 17(4):254-9. PubMed ID: 2242280
[TBL] [Abstract][Full Text] [Related]
13. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward J
Clin Cancer Res; 2015 Apr; 21(8):1802-9. PubMed ID: 25878361
[TBL] [Abstract][Full Text] [Related]
14. Expression of ras-P21 in salivary gland tumors.
Kusama K; Chu L; Suzuki T; Okutsu S; Kudo I; Moro I
Adv Exp Med Biol; 1995; 371B():1187-90. PubMed ID: 7502781
[No Abstract] [Full Text] [Related]
15. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.
Dajee M; Lazarov M; Zhang JY; Cai T; Green CL; Russell AJ; Marinkovich MP; Tao S; Lin Q; Kubo Y; Khavari PA
Nature; 2003 Feb; 421(6923):639-43. PubMed ID: 12571598
[TBL] [Abstract][Full Text] [Related]
16. REDD1, a new Ras oncogenic effector.
Smith ER; Xu XX
Cell Cycle; 2009 Mar; 8(5):675-6. PubMed ID: 19242117
[No Abstract] [Full Text] [Related]
17. Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.
Triozzi PL; Stoner GD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):185-92. PubMed ID: 9346851
[TBL] [Abstract][Full Text] [Related]
18. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
Shalom-Feuerstein R; Lindenboim L; Stein R; Cox AD; Kloog Y
Cell Death Differ; 2004 Feb; 11(2):244-7. PubMed ID: 14576773
[No Abstract] [Full Text] [Related]
19. Specific repression of mutant K-RAS by 10-23 DNAzyme: sensitizing cancer cell to anti-cancer therapies.
Yu SH; Wang TH; Au LC
Biochem Biophys Res Commun; 2009 Jan; 378(2):230-4. PubMed ID: 19014906
[TBL] [Abstract][Full Text] [Related]
20. Oncogenes and oncoproteins in occupational carcinogenesis.
Brandt-Rauf PW
Scand J Work Environ Health; 1992; 18 Suppl 1():27-30. PubMed ID: 1357742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
